IPIX
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q1 | -0.00 | $0 | -$679,000 |
| 2023 Q4 | -0.00 | -$6,000 | -$381,000 |
| 2023 Q3 | -0.00 | $0 | -$486,000 |
| 2022 Q2 | -0.00 | $0 | -$504,000 |
| 2022 Q1 | -0.00 | $0 | -$795,000 |
| 2022 Q4 | -0.00 | $18,000 | -$988,000 |
| 2022 Q3 | -0.00 | $0 | -$1M |
| 2021 Q2 | -0.00 | $0 | -$2M |